ACN Newswire

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration

15 8 月, 2025

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration (“wet-AMD”) in China.The phase 3 clinical trial of EB12-20145P (HLX04-O) among Chinese patients (“AURA-1”) has successfully reached the primary endpoint in April this year. AURA-1 is a multi-centre, randomised, double-blind, active-controlled, and non-inferiority phase 3 clinical trial which aimed to compare the efficacy and safety of EB12-20145P (HLX04-O) with that of ranibizumab administered by intravitreal injection (“IVT”) in newly diagnosed wet-AMD patients.In addition to AURA-1, the BLA of which has been validated by the NMPA, an international, multi-centre phase 3 clinical study of EB12-20145P (HLX04-O) in patients with wet-AMD is ongoing successively in several European countries, Australia, the United States, and China (“AURA-2”) with last patient last visit completed by January 2025. Moving forward, Essex will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.About wet-AMDAge-related macular degeneration (“AMD”) is one of the leading causes of visual impairment and blindness in the elderly worldwide [1]. According to the World Health Organization (WHO), about 30 million people have suffered from AMD globally, and about half a million people become blind due to AMD each year [2]. Wet age-related macular degeneration (“wet-AMD”) is characterised by the formation of subretinal choroidal neovascularization (CNV) and is responsible for approximately 90% of cases of AMD-related blindness. Due to an aging population, wet-AMD has become a serious social medical problem and indicated a huge burden of unmet need [3]. With the development of treatment for fundus diseases, anti-VEGF drugs are becoming the first-line therapy for the management of wet-AMD [4], and the efficacy and safety of vitreous injection of bevacizumab for wet-AMD have been verified in multiple clinical studies [5-11].About EssexEssex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.Reference[1] 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

Re-opening of Food Expo and concurrent fairs

15 8 月, 2025

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

WL Delicious Announced 2025 Interim Results

15 8 月, 2025

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Weilong Delicious Global Holdings Ltd (“WL Delicious” or the “Company”) and together with its subsidiaries (the “Group”) (Hong Kong stock code: 9985.HK) announced its unaudited interim results for the six months ended 30 June 2025 (the “Reporting Period”).RMBFor the 6 months ended 30 June20252024ChangeRevenue3,483 million2,939 million+18.5%Gross Profit1,642 million1,462 million+12.3%Gross Profit Margin47.2%49.8%-2.6p.p.Net Profit736 million621 million+18.5%Net Profit Margin21.1%21.1%Remain stableInterim Dividend0.18 / ordinary share0.16 / ordinary share+12.5%In the first half of 2025, despite global consumption growth facing general pressure, China remained one of the world’s largest consumer markets. Benefiting from the steady growth momentum of China’s snack food market in recent years, during the Reporting Period WL Delicious kept pace with industry development trends by adhering to its multi-category strategy,  focusing on innovation, conducting in-depth consumer  insights, accurately capturing market demand, and continuously strengthening its R&D capabilities, while further deepening brand penetration through approaches favored by young consumers, by creating multi-dimensional consumption scenarios and connections through various online and offline brand activities, the Group continuing to enhance its omnichannel coverage and sales network, thereby providing better services and experiences for clients and consumers.During the Reporting Period, WL Delicious' business strategy delivered substantial outcomes, with operational performance continuing to rise steadily, both revenue and net profit recording double-digit growth. In the first half of 2025, the Group achieved a total revenue of RMB3,483 million, representing a year-on-year growth of 18.5% primarily due to the Group’s continuous efforts in strengthening omni-channel development and brand building, as well as optimizing the channel structure during the reporting period. Despite the increase in certain raw material costs during the Reporting Period, which caused the Group's gross profit margin declined by 2.6 percentage points from 49.8% in the corresponding period of the Previous Year to 47.2%; gross profit still rose by 12.3% year-on-year to RMB 1,642.4 million, driven by both revenue growth and the Group’s active enhancement of supply chain efficiency. At the same time, benefiting from the increase in the Group's operating profit, net profit for the Reporting Period grew by 18.5% year-on-year to RMB 736.2 million, while the net profit margin remained at the same level year-on-year at 21.1%.Based on the overall performance during the Reporting Period, the Board of Directors has resolved to the distribution of the interim dividend of RMB0.18 per share, representing a payout ratio of approximately 60%. The dividend is expected to be paid on or about October 20, 2025.In terms of products, the Group adhered to a strategy of multiple categories, making efforts in terms of new products, new flavors, new craftmanship, and new packaging, such as expanding the boundaries of flavor innovation and responding in depth to consumers’ demand for innovative flavors. During the Reporting Period, the Group launched a number of new products such as sesame paste-flavored “Konjac Shuang” and spicy beef-flavored “Kiss Burn”, further expanding and enriching the product portfolio, enhancing product quality, meeting the diverse and personalized consumption needs of the market, and driving a stronger match between product strength and market demand.In terms of brand development, the Group continued to deepen brand penetration through approaches favoured by young consumers, building multi-dimensional consumer scenarios and connections through various online and offline brand activities. For example, the Group partnered with LINLEE to initiate the “Spicy Challenge”, leveraging its best-selling products and buzz to reach more consumers; collaborated with the domestic trend brand Crying Center to launch the “Big Kids Exclusive” series, using holiday marketing to evoke youthful taste memories. In addition, the Group officially announced Mr. WANG Anyu as the spokesperson for its Konjac products, leveraging the influence of celebrities to broaden the channels of communication. This series of measures effectively reached the young customer base and solidified the foundation for the brand’s youthful and fun-oriented development.In terms of distribution channels, the Group continued to advance its offline omni-channel and online all-platform coverage strategy. With the emergence of new channel market practice, the Group kept pace with channel changes, continuously expanding POS network,  strengthening the sales team’s execution capability at the POS , collaborating with distributors to upgrade POS services and product availability, in order to drive steady growth in offline POS performance. On traditional e-commerce platforms, the Group also actively expanded its presence, building an all-platform ecosystem to ensure effective synergy with offline channels and to facilitate the implementation of its omni-channel development strategy.In addition, the Group has remained committed to automation upgrades and technological innovation breakthroughs in its production facilities, while accelerating the digital transformation of its business systems. On this basis, the Group has continuously strengthened organisational development and the building of its core talent pipeline, thereby enhancing overall operational efficiency and injecting strong momentum into the sustainable and steady development of its business.Mr. Liu Weiping, Chairman of WL Delicious, stated: "The Group will remain committed to its ‘multi-category’ product strategy, uphold product innovation, continue to strengthen brand building, and further reinforce WL Delicious’ brand image and distinctive positioning as youthful, fun, and creative. At the same time, the Group will actively embrace change, continuously enhance its omnichannel coverage capabilities, and provide consumers with more convenient consumption experiences. Looking ahead, the Group will embrace market changes with a more proactive mindset, continually enhance our competitiveness with better products, higher-quality services, and improved experiences, and create more value for consumers, customers, shareholders, investors, employees, and society as a whole."About Weilong Delicious Global Holdings LtdWEILONG Delicious Global Holdings Limited ("WL Delicious") is an all-in-one spicy snack products enterprise, leading in the research and development, production, and sales of spicy snack foods in China. Based on traditional formulas, WL Delicious started the Chinese seasoned flour products (also commonly known as Latiao industry, created our first Latiao  snack in 2001, leading the standards construction of Latiao industry. With our outstanding product development capabilities, the Group has successfully diversified into vegetable products, bean-based products and others, including Konjac Shuang , Fengchi Kelp , XIAO MO NV and others. WL Delicious is a popular snack food brand among young consumers in China. It has an omni-channel sales and distribution network that effectively reaches young consumers. For more information, please visit: https://www.weilongshipin.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements

15 8 月, 2025

RAS AL KHAIMAH CITY, UAE, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Ras Al Khaimah International Corporate Centre (RAK ICC) has announced significant amendments to its Foundations Regulations 2019, which took effect on 31 July 2025. The changes represent one of the most substantial updates to the regime since its introduction, reinforcing the UAE's position as a competitive jurisdiction for wealth structuring and long-term asset protection.RAK ICC Foundations are widely recognized for their flexibility, confidentiality, and legal robustness, making them a preferred choice for high-net-worth individuals, entrepreneurs, and family offices, both within the UAE and internationally. These structures are commonly used for succession planning, family governance, and consolidating diverse assets under a single legal entity.The 2025 amendments introduce stronger legal safeguards and improved governance measures which include:Firewall Provisions - Stronger protection from foreign judgments conflicting with RAK ICC Regulations.Three-Year Statute of Limitations - Limits challenges to establishment or asset transfers to three years.Cause of Action Provisions - Creditor fraud claims are limited to the specific asset involved and only if rendering the founder insolvent.Duress and Officer Protections - Nullifies actions taken under foreign legal coercion, preserving internal governance autonomy of a foundation.Strengthened Arbitration Framework - Disputes can be resolved privately with court-level powers.Private Trustee Foundation Provisions - Clarifies asset segregation and fiduciary integrity for property held in trust by a foundation.Assets held within RAK ICC Foundation will now benefit from enhanced firewall provisions, ensuring that foreign judgments conflicting with UAE law cannot be enforced against them. A new three-year limitation period has been established for challenging the formation of a foundation or the transfer of assets into it, providing greater certainty for founders and beneficiaries. The reforms also tighten creditor protection rules by requiring proof of insolvency in fraudulent transfer claims, with liability capped at the value of the disputed asset to prevent overreach into unrelated holdings.In addition, the updated regulations address governance integrity and operational resilience. Officers of a foundation who receive foreign orders inconsistent with RAK ICC law are obligated to disregard them, thereby safeguarding the autonomy of the foundation's decision-making. The framework now explicitly confirms that assets held in trust by a foundation are legally distinct and separate from foundation property, ensuring clear asset segregation. Dispute resolution has also been strengthened, with arbitration provisions expanded to grant tribunals court-like powers, enabling disputes to be resolved efficiently, confidentially, and in line with international best practices.These changes are part of RAK ICC's broader strategy to maintain a forward-looking legal and regulatory environment that meets global standards while catering to the specific needs of its client base. They reflect the jurisdiction's commitment to supporting sophisticated wealth planning strategies that balance control, privacy, and long-term security.By enhancing its Foundations regime, RAK ICC is cementing its position in the UAE as a trusted partner for those seeking secure, adaptable, and internationally compliant solutions for wealth preservation and intergenerational planning.About RAK ICCRas Al Khaimah International Corporate Centre (RAK ICC) is a corporate registry based in Ras Al Khaimah, United Arab Emirates. The organisation provides international business companies and foundations, typically used for private and business structuring, asset consolidation, and succession planning. To date, RAK ICC has incorporated thousands of international companies and supports multi-billion dirhams in structured assets. It serves high-net-worth individuals, entrepreneurs, and businesses seeking flexible and secure solutions for long-term business and wealth management.For media enquiries, contact us at:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/SOURCE: RAK ICC Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

越秀房产基金整体经营稳定 实现收入逾人民币9.66亿元

15 8 月, 2025

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 越秀房地产投资信托基金（「越秀房产基金」，连同越秀房托资产管理有限公司，统称「基金」；股份代号：405）公布其截至2025年6月30日止六个月之中期业绩。越秀房产基金管理团队：主席及非执行董事江国雄先生（中）、执行董事及行政总裁区海晶女士（左）、财务总监关志辉先生（右）2025年中期业绩摘要：- 整体经营稳定，收入总额为人民币9.66亿元（2024年同期：人民币10.34亿元）。- 于2025年6月30日，物业整体出租率为82.2%（2024年同期：84.0%）。- 平均融资成本为3.33%，较年初下降83个基点，剔除汇兑亏损的融资成本同比减少13.5%。- 中期分派每个基金单位约人民币0.0333元，约等于0.0366港元。按年计算的分派收益率为8.42%。广州国金中心：- 广州国金中心综合体录得经营收入为人民币4.86亿元，占基金收入总额50.3%。- 广州国金中心写字楼引进一家财富世界500强背景企业；出租率为82.6%；续约率为70%。- 国金天地期内出租率高达96.4%。- 广州四季酒店平均入住率同比上升1.1个百分点，客房收入创历史同期新高；国金中心雅诗阁服务式公寓平均入住率同比增长1.8个百分点，营业收入亦创历史同期新高。广州越秀金融大厦：- 越秀金融大厦录得经营收入约人民币1.65亿元，占基金收入17.1%，出租率达82.1%。- 租户结构不断优化，新引进优质租户包括一家财富世界500强背景企业，以及一家市值超百亿的期货企业。积极管理融资风险，有效平抑融资成本- 针对2025年上半年到期的人民币5.3亿元短期贷款、21亿港元5年期银团贷款及今年内到期的其他贷款，管理人于2025年上半年完成人民币5.3亿元短期贷款续借，并通过取得人民币17亿元境外贷款和发行人民币10亿元点心债，用于到期贷款的再融资及提前置换，确保流动性风险得到有效管控。- 管理人期内合计引入人民币32.3亿元贷款，并置换境外浮息港元贷款，利用人民币融资相对低位，主动调节融资结构，降低利率市场冲击。2025年上半年末融资利率敞口约为14%，较年初26%收窄12个百分点；平均融资成本为3.33%，较年初4.16%下降83个基点；上半年平均付息率3.92%，同比下降64个基点。剔除汇兑亏损的融资成本约为人民币4.02亿元，同比减少13.5%。- 2025年6月末人民币融资约147.95 亿元，占总体融资72%（2024年同期：人民币融资约84.04 亿元，占总体融资41%）。越秀房产基金主席及非执行董事江国雄先生表示：「2025年上半年，在全球贸易环境波动及经济增长放缓的背景下，中国国内生产总值GDP同比增长5.3%，但企业扩张保守缓慢；零售消费疲弱、酒店公寓房价承压。为应对行业不利因素，我们策略性抢占市场份额，提前推进续租工作，投入资本性改造，提升产品竞争力，有效稳住经营基本面，为中期经营收入提供坚实支撑。同时，融资成本回落也为分派创造有利条件。」国金中心国金中心透过提升产品和优化营运，客户访问量和转化率均录得正向提升，新签13,133平方米。推出4,235平方米带装修单元去化周期仅约十九天，去化率接近九成。引进优质租户包括一家财富世界500强背景企业、一家全球龙头航运企业和一家知名互联网背景文体娱乐企业，合计超过2,200平方米。续租9,099平方米，续租率70%，留存优质租户包括两家财富世界500强背景企业和一家外国领事馆。国金中心入选观点「表现力指数·2025商办资产运营表现」TOP30榜单。国金天地积极打造电子化消费场景，推进悦秀会本地生活平台试点落地，已覆盖12家商户，同时利用大众点评、云闪付等平台多渠道引流，新签和续租合计5,734平方米，续租率97%。出租率为96.4%。期内，中免免税店宣布落户国金天地，预计第三季度开业，成为广州首家且目前唯一的市内免税店。广州四季酒店客房收入和国金中心雅诗阁服务式公寓营业收入分别创历史同期新高。广州四季酒店期内平均入住率为80.1%，同比上升1.1个百分点；平均房价为人民币2,201元，与去年同期相若；每间可供出租客房收入(RevPAR)为人民币1,762元，同比增长0.7%；RevPAR竞争指数为111.7，在奢华酒店竞争群组中始终保持较领先的市场地位。国金中心雅诗阁服务式公寓期内平均入住率为92.3%，同比上升1.8个百分点，平均入住率高于竞争群公寓9.7个百分点；平均房价为人民币1,128元，与去年同期相若；RevPAR为人民币1,041元，同比增长1.5%；RevPAR竞争指数达120.0。越秀金融大厦越秀金融大厦期内新签7,448平方米，包括七家租户扩租合计1,500平方米。推出7,089平方米带装修单元，去化周期约38天，去化率超过六成半。新引进优质租户包括一家财富世界500强背景企业，以及一家市值超百亿的期货企业。受部分租户回迁自有物业办公的影响，续租10,303平方米，续租率42%。留存大面积优质租户包括国际四大之一「德勤」和一家国内龙头综合性资产管理公司。白马大厦白马大厦引入珠三角供应链资源，期内带动新签3,273平方米，实现一楼满租。上半年累计接待165个采批团，累计接待采购商近5,000人次，其中包括来自法国、越南等23个外商团，促成采购金额达人民币1.4亿元。白马大厦依托大湾区国际女装展、广交会等展会促进租户成交，亦成功推出「白马悦境通」跨境电商平台和「白马商学院营销赋能营」系列课程，激活租户数字化运营新动能。财富广场财富广场期内新签2,354平方米，引进优质租户包括一家财富世界500强综合金融集团旗下医疗养老板块的数家企业。续租2,924平方米，续租率76%，留存优质租户包括一家财富世界500强背景企业，亦灵活匹配降本需求调整单元挽留租户。城建大厦城建大厦期内新签7,585平方米，引进一家美容科技企业提升楼内大健康业态氛围。结合租户降本意愿制定挽留方案，优化产品标准匹配租户需求。续租2,090平方米，续租率68%，包括一家全球知名合同研究组织(CRO)的广州办公室。维多利广场维多利广场期内主力租户「优衣库」继续发挥旗舰作用，首发C系列产品，并于3月28日至4月6日落地全国首场「优衣库美好生活市集」、巨型宝可梦及美好生活音乐活动，活动期间达季度客流峰值，带动四月销售额同比增长7%，推动中期期间销售额同比增长0.3%。项目联动餐饮租户，抓住客流高峰提升销售，带动中期期间项目整体销售额同比增长0.6%。上海越秀大厦上海越秀大厦期内续租3,798平方米，续租率39%；新签3,933平方米，迅速填补退租单元。通过更换停车场节能灯管提升场内亮度，项目实现节能效益和服务水平双提升，提高租户满意度。于中期期末，上海越秀大厦出租率为87.2%，同比增加2.6个百分点。武汉物业武汉越秀财富中心期内新签12,395平方米，引进优质租户包括一家全球领先汽车集团成员企业和一家多元化专业服务企业。续租10,884平方米，续租率81%，留存大面积优质租户包括一家财富世界500强背景央企。招商团队透过单元局部微改造、软装提升、打造智能样板间等多种方式优化客户看楼体验，提升客户转化率。星汇维港购物中心期内新签和续租合计3,894平方米，续租率82%。成功引进多家热门餐饮品牌，包括A馆一楼引进网红品牌「达美乐」，带动更多家庭客群。项目开拓夜间消费，利用四楼「悦花园」亮点优势，持续打造「江畔星夜」、「深夜食堂」激发销售新增长点。杭州维多利杭州维多利期内新签1,974平方米，引进一家全层租户。续租6,083平方米，续租率64%，留存优质租户包括一家财富世界500强背景建筑工程企业和一家山西省属国企的浙江分公司。未来展望市场普遍憧憬美联储下半年进一步降息，但路径和幅度仍具不确定性。另一方面，今年是中国「十四五」规划收官之年，各项政策稳字当头，包括适度宽松货币政策和「以旧换新」消费补贴政策，旨在通过扩大内需激发市场活力，因此管理人预期人民币利率将维持较低水平。伴随国内新质生产力加快培育发展和供给侧改革深化推进，管理人预期产业动能继续推陈出新，营商气氛将向好改善。备受瞩目的第十五届全国运动会将于下半年在广州开幕，有望带动商场消费和酒店公寓需求。下半年，管理人将因应经济发展走势动态实施积极、稳健、灵活的租赁策略，敏锐把握潜在机会，持续提升资产组合市场竞争力。管理人将视市场发展预期对融资结构持续检视并进行合理调整，通过各类人民币融资途径，引入低成本人民币融资，以寻求更优融资成本，平滑利率风险。管理人将按计划开展相关资本性改造工程，合理规划和分段改造广州四季酒店客房，围绕产品提升、设备更新和安全保障维度，实现物业保值增值，为项目稳健经营保驾护航。关于越秀房地产投资信托基金越秀房地产投资信托基金（「越秀房产基金」）于2005年12月21日在香港联交所上市，为全球首只投资于中国内地物业的上市房地产投资信托基金。越秀房产基金目前持有的物业组合包括位于广州的广州国际金融中心、白马大厦、财富广场、城建大厦、维多利广场、越秀金融大厦、位于上海的越秀大厦、位于武汉的武汉物业（包括武汉越秀财富中心和星汇维港购物中心）、位于杭州的维多利商务中心以及位于香港的越秀大厦共10项高素质物业，物业产权面积共约118.4万平方米，分别位于中国广州市、上海市、武汉市、杭州市及香港市的核心商业区域。物业类型包括甲级写字楼、商业综合体、零售商业、酒店、服务式公寓、服装专业市场等。传媒查询:纵横财经公关顾问有限公司李惠儿电话: +852 2864 4834电邮：sprg_yx@sprg.com.hk梁家仪电话: +852 2114 4172张铭伊电话: +852 2864 4903网址:http://www.sprg.com.hk  Copyright 2025 亚太商讯 via SeaPRwire.com.

ACN Newswire

云顶新耀维长宁（艾曲莫德）在中国台湾新药上市申请获受理 亚洲市场准入再迎里程碑

15 8 月, 2025

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，中国台湾地区药政主管部门（TFDA）已正式受理维长宁（艾曲莫德，中国台湾地区商品名："維長寧"）用于治疗中重度活动性溃疡性结肠炎（UC）患者的新药上市许可申请（NDA）。这一进展标志着艾曲莫德继在中国澳门、新加坡和中国香港获批以及韩国NDA获正式受理之后，在亚洲市场的准入取得又一重大里程碑。中国国家药品监督管理局也于2024年12月正式受理艾曲莫德（维适平(R)）的新药上市申请，预计将在今年年底或明年年初获批。艾曲莫德是一款针对溃疡性结肠炎，每日一次的口服一线治疗药物，能够强效实现肠道黏膜愈合，且使用便捷，并具有良好的安全性特征。黏膜愈合是国内外溃疡性结肠炎临床指南一致认定的溃疡性结肠炎治疗目标。溃疡性结肠炎患者尽早实现黏膜愈合，可大幅降低疾病复发率、住院率、结直肠切除手术率和结直肠癌发生风险。艾曲莫德已被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。2025年，艾曲莫德获得2025年美国胃肠病学会（ACG）成人UC临床指南的一线治疗推荐，进一步印证了其全球专业共识下的临床价值。云顶新耀首席执行官罗永庆先生表示："此次在中国台湾地区NDA申请的正式受理，是维长宁亚洲商业化进程中的又一重要进展。随着亚洲地区溃疡性结肠炎患者人数持续增长，临床上存在巨大未满足需求。仅在中国，2024年溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人。患者面临长期治疗与生活质量的双重挑战。此次受理充分体现了对维长宁临床价值的高度认可。我们将继续加快这一创新疗法在中国大陆及亚洲其他市场的上市进程，提升可及性，帮助患者实现长期疾病控制并改善生活质量。"本次申请基于ELEVATE UC III期注册研究（ELEVATE UC 52和ELEVATE UC 12）和ENLIGHT研究（ES101002）的结果。ELEVATE UC III期注册研究显示，在既往常规治疗、生物制剂或JAK抑制剂治疗失败或不耐受的中重度活动性溃疡性结肠炎患者中，每日一次2mg艾曲莫德在第12周和第52周均显示卓越且持久的临床缓解和内镜下深度黏膜愈合，且安全性良好，与既往研究一致。同时，ENLIGHT研究作为迄今最大规模的亚洲中重度UC III期注册临床研究，在中国大陆、中国台湾及韩国开展，共纳入340名患者。研究结果显示，艾曲莫德在诱导期和维持期均取得了显著且具有统计学意义的疗效优势，为其在亚洲人群中的应用提供了有力证据支持。作为云顶新耀在自身免疫性疾病领域的重磅产品，艾曲莫德已于2024年被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录，在大湾区先行使用，惠及UC患者，并成为公司第三款商业化新药。今年3月，云顶新耀已启动艾曲莫德在嘉善工厂的本地化生产建设项目，以支持其在大中华区及亚洲其他市场的供应与商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.